Trazodone versus doxepin as a pharmacologic sleep aid in psychiatric inpatients: A retrospective cohort study [0.03%]
一项回顾性队列研究：在住院精神疾病患者中使用曲唑酮和多塞平作为药物助眠手段的比较
Kevin Chen,Megan Maroney
Kevin Chen
Introduction: Trazodone and doxepin are non-habit-forming options often used to treat insomnia in the psychiatric inpatient population. At our institution, trazodone 50 mg is the suggested initial treatment for insomnia i...
Lauren Steil,Dale Terasaki,Rebecca Reiss et al.
Lauren Steil et al.
Introduction: Alcohol use disorder (AUD) is associated with significant morbidity and mortality, contributing to 5% of annual deaths. Although some literature suggests that acamprosate is an effective treatment for AUD, i...
Community pharmacy attitudes and behaviors following a buprenorphine best practices dissemination [0.03%]
社区药店在分发布洛品最佳实践后的态度和行为变化
Winter Roth,David Dadiomov
Winter Roth
Introduction: Opioid overdose deaths continue to rise despite available safe and efficacious treatments for opioid use disorder, such as buprenorphine. Whereas provider-level access to buprenorphine has improved, communit...
A model for timely dissemination of critical information: Clozapine toxicity during the COVID pandemic [0.03%]
及时传播重要信息的模型：COVID流行期间的clozapine毒性问题
Jessica Gannon,K N Roy Chengappa,Robert O Cotes et al.
Jessica Gannon et al.
Clozapine is the only medication approved for treatment-resistant schizophrenia. Clozapine toxicity associated with COVID-19 infection could be amplified by concomitant nirmatrelvir/ritonavir. Knowledge gaps among clinicians and patients le...
Danielle L Stutzman
Danielle L Stutzman
Amy Werremeyer,Greg Payne
Amy Werremeyer
Transitions of care: Assessment of adherence to long-acting injectable antipsychotic treatment following discharge from inpatient psychiatry [0.03%]
护理过渡：出院后对长效注射抗精神病治疗依从性的评估
Charnae Ross,Katie S Adams,Ericka L Crouse
Charnae Ross
Introduction: Long-acting injectable antipsychotics (LAI-APs) are used in patients with chronic psychiatric disorders as a strategy to manage oral medication nonadherence. Inpatient LAI-AP administration may assist with transition to the ou...
Pharmacist administration of long-acting injectable medications for substance use disorders: A scoping review [0.03%]
物质使用障碍长效注射药物的药剂师管理：系统性回顾
Pamela Hernandez Bustamante,Amanda Charles,Marissa Snider et al.
Pamela Hernandez Bustamante et al.
Introduction: Using long-acting injectable (LAI) medications increases treatment adherence and promotes positive outcomes for patients with substance use disorders (SUD). Despite documented benefits that LAI medications can have over their ...
Clinical pearls for the management of duloxetine patients with medical comorbidities [0.03%]
伴有合并症的度洛西汀患者的管理临床经验珠玑
Megan O&#x;Connell,Amy VandenBerg
Megan O&#x;Connell
The effective use of duloxetine can be complicated by acute kidney injury, acute and/or chronic hepatic dysfunction, dysphagia, enteral nutrition, and common pharmacokinetic interactions. This article aimed to review the pharmacological pro...
Clinical experience and treatment considerations with vesicular monoamine transport 2 inhibitors [0.03%]
临床使用以及对vmat-2抑制剂的治疗思考
Kayla Johnson
Kayla Johnson
Vesicular monoamine transporter 2 inhibitors (VMAT2i) are currently Food and Drug Administration-approved for the treatment of Huntington disease chorea and tardive dyskinesia. Additionally, they are often used for other hyperkinetic moveme...